Structure of compound CC-92480

CRBN-based selective IKZF1/3 degrader

oral efficacy in lenalidomide-resist. xenograft

from phenotypic screen and optimization

J. Med. Chem., Mar. 4, 2020

Celgene, San Diego, CA

CC-92480 (Celgene/Bristol Myers Squibb (BMS) oral in vivo CRBN-based selective IKZF1/3 degrader)

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.